This page contains a list of scientific journal articles that have cited BPS products and services since 2013. We would like to congratulate all our loyal customers on their contributions to the scientific community. Our customers are truly amazing and dedicated scientists and this is evidenced by the outstanding research they are doing. 

Search By Product Name or Catalog Number

NameTitle
10X HAT Assay Buffer (50095) Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies
P300 Homogeneous Assay Kit (50078) The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies
p300/KAT3B (50071) Pyrido- and benzisothiazolones as inhibitors of histone acetyltransferases (HATs)
NALP3 (CIAS1), His-FLAG-tags (80117) Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease

BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination
Anti-GAPDH, Monoclonal (25007) Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3–Induced Myocarditis
Anti–H3K27ac monoclonal antibody (25238) ATAC-see reveals the accessible genome by transposase-mediated imaging and sequencing
Anti-HDAC2 monoclonal antibody (25288) Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity
Anti-FLAG-Tag, Monoclonal (25003) Genetic pathways controlling CNS development
Anti-PD-1 Neutralizing Antibody, PE-labeled (71290-2) PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+cancer cells
CRE Reporter Kit (60611) Nuclear TRAF3 is a negative regulator of CREB in B cells
EGFR Kinase Assay Kit (40321) Design and Synthesis of 4‐Anilinothieno[2,3‐d]pyrimidine‐Based Compounds as Dual EGFR/HER‐2 Inhibitors
FOXO Reporter Kit (60643)

1. Barley sprout extracts reduce hepatic lipid accumulation in ethanol-fed mice by activating hepatic AMP-activated protein kinase

2. Chamaejasmine induces apoptosis in HeLa cells through the PI3K/Akt signaling pathway

3. FOXO responses to Porphyromonas gingivalis in epithelial cells.

GCN5 Fluorogenic Assay Kit (50091)

Role of extracellular Hydrogen peroxide in regulation of iron homeostasis genes in neuronal cells: Implication in iron accumulation.

Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay

Histone Ribosylation Assay Kit (80579) The discovery and characterization of K-756, a novel Wnt/β-catenin pathway inhibitor targeting tankyrase
HSP90α C-Terminal Domain TR-FRET Assay Kit (50289) Design, synthesis, and anticancer activity of C8-substituted-4′-thionucleosides as potential HSP90 inhibitors
HSP90α Inhibitor Screening Assay Kit (50317) Hitting a Moving Target: How Does an N‐Methyl Group Impact Biological Activity?Design, synthesis, and anticancer activity of C8-substituted-4′-thionucleosides as potential HSP90 inhibitors
NF-κB Reporter Kit (60614) Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells

Effects of angiotensin-(1-7) on the proliferation and collagen synthesis of arginine vasopressin-stimulated rat cardiac fibroblasts: role of mas receptor-calcineurin-NF-κB signaling pathway.
Notch1/CSL Reporter Kit (Notch Signaling Pathway) (60509) Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
P300 (KAT3B) Fluorogenic Assay Kit (50092) Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms
PD-1:PD-L2 TR-FRET Assay Kit (72012) Salicylates are interference compounds in TR-FRET assays
SBE Reporter Kit (TGFβ/SMAD signaling pathway) (60654) Papel de MUC1 en la Fibrosis Pulmonar Idiopática
SETD2 Chemiluminescent Assay Kit (52060) Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives
Biotin-PEG12-NHS Ester (27446) Pipette tip biosensors for bacterial double-stranded DNA using bioluminescence induced by zinc finger luciferase
BRD4 (BD1+BD2) (31047) Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
BRD4 (BD1+BD2), GST-tag (31044) CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model
BRD4 (BD2) Inhibitor Screening Assay Kit (32524) Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
NF-κB reporter (60650) The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
TAF1L (BD1+BD2), GST-tag (31107) Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
ARE reporter cell line (Nrf2 antioxidant pathway) (60513)

1. Activation of anti-oxidant Nrf2 signaling by substituted transstilbenesThe role of plant processing for the cancer preventive potential of Ethiopian kale (Brassica carinata)

2. The role of plant processing for the cancer preventive potential of Ethiopian kale (Brassica carinata)

3. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors

4. Regulation of Gene Expression by the Cd44- Intracytoplasmic Domain (CD44-ICD)

ARE Reporter Kit (Nrf2 Antioxidant Pathway) (60514)

1. Role of extracellular Hydrogen peroxide in regulation of iron homeostasis genes in neuronal cells: Implication in iron accumulation.

2. Mecanismos neuroquímicos associados aos efeitos tipo-antidepressivo e neuroprotetor de inosina

3. Protective effects of rosmarinic acid against hydrogen peroxide‑induced cellular senescence and the inflammatory response in normal human dermal fibroblasts

4. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response

5. Melanocyte‐protective effect of afzelin is mediated by the Nrf2‐ARE signalling pathway via GSK‐3β inactivation

6. Pharmacological stimulation of nuclear factor (erythroid-derived 2)-like 2 translation activates antioxidant responses

Hippo Pathway TEAD Reporter - MCF7 Recombinant Cell Line (60618)

A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis

Myc Reporter (Luc) – HCT116 Recombinant Cell Line (Myc Signaling Pathway) (60520)

Dynamic expression of tRNA-derived small RNAs define cellular states

NF-κB reporter (60650)

LRRC8A channels support TNFα-induced superoxide production by Nox1 which is required for receptor endocytosis

TCF/LEF Cell Line (60531)

Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation

Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/α-albumin

TCF/LEF reporter-HEK293 Recombinant cell line (Wnt Signaling Pathway, Lithium Chloride Dependent) (60501)

Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity

TGF/SMAD Signaling Pathway SBE Reporter – HEK293 Cell Line (60653)

Functional Adenosine Receptor 2B Drives Profibrotic and Proinflammatory Signaling in Renal Fibroblasts Through Modulation of TGFβ Receptor Signaling

PCSK9[Biotinylated]-LDLR Binding Assay Kit (72002)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

Anti-PCSK9 Neutralizing Antibody(71207)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

Mouse bFGF (90112-B)

Pivotal role of phospholipase D1 in tumor necrosis factor-α-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice.

Mouse Interleukin-2 (90185-B)

Förster Resonance Energy Transfer to Study TCR-pMHC Interactions in the Immunological Synapse

EX527 (27103)

Cyclocarya paliurus extract activates insulin signaling via Sirtuin1 in C2C12 myotubes and decreases blood glucose level in mice with impaired insulin secretion

Fluorogenic HDAC Class 2A Substrate (50040)

1. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.

2. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach

3. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

4. Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain

Fluorogenic HDAC Substrate 1 (50032)

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

Fluorogenic HDAC Substrate 2(Green Fluorescence) (50038)

1. The first report of direct inhibitors that target the C-terminal MEEVD region on heat shock protein 90

2. Investigating the selectivity of metalloenzyme inhibitors.

3. Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition

4. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer

Fluorogenic HDAC Substrate 3 (50037)

1. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.

2. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease

3. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease

4. Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain

Fluorogenic SIRT substrate 1 (50080)

Response to exogenous gonadotropins in the unresponsive ovary syndrome.

HDAC Assay Buffer (50031)

1. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.

2. Investigating the selectivity of metalloenzyme inhibitors.

3. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities

HDAC Assay Developer (50030)

1. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.

2. Investigating the selectivity of metalloenzyme inhibitors.

3. Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain

HDAC1, FLAG-tag, His-tag (50051)

1. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors (2017)
2. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation (2017) 
3. Screening of histone deacetylase 1 inhibitors in natural products by capillary electrophoresis (2017) 
4. (±)-Applanatumines B–D: novel dimeric meroterpenoids from Ganoderma applanatum as inhibitors of JAK3 (2017)
5. Synthese, Konformationsanalyse und biologische Evaluierung von neuartigen antitumoraktiven Peptoid-Derivaten (2017)
6. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines (2017)
7. Discovery of an Inhibitor of the Proteasome Subunit Rpn11 (2017)
8. Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1  (2017)
9. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity (2017)
10. Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors (2017)
11. An azumamide C analogue without the zinc-binding functionality (2017)
12. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
13. Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity (2017)
14. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
15. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015) 
16. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
17. CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis (2014)
18. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents (2014) 
19. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
20. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
21. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
22. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors(2014) 
23. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
24. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
25. Thermodynamics of ligand binding to histone deacetylase like amidohydrolase from Bordetella/Alcaligenes (2014) 
26. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
27. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
28. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
29. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
30. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
31. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
32. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni (2013) 
33. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors(2013

HDAC2, His-tag (50002)

1. Exploration of some indole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
4. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
5. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015) 
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015) 
7. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction (2015) 
8. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
9. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
10. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
12. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging (2014) 
13. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
14. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
15. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
16. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
17. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
18. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
19. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
20. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
21. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013) 
22. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013

HDAC2, FLAG-tag (50052)

1. Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers (2015) 
2. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
3. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
4. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
5. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
6. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
7. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
8. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
9. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
10. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013) 
11. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013)

HDAC3 (50003)

1. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Molecular Simulation and Activity Studies of Oxametacin as an HDAC Inhibitor (2017)
4. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
5. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015) 
7. Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia (2015) 
8. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
9. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
10. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
12. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
13. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
14. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
15. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
16. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
17. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
18. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni (2013)

HDAC4 (50004)

1. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Molecular Simulation and Activity Studies of Oxametacin as an HDAC Inhibitor (2017)
4. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
5. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015) 
7. Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia (2015) 
8. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
9. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
10. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
12. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
13. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
14. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
15. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
16. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
17. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA (2013) 
18. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni (2013)

HDAC5 (50005)

1. An azumamide C analogue without the zinc-binding functionality (2017)
2. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
3. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
4. Identification and characterization of small-molecule inhibitors of lysine acetyltransferases (2014) 
5. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
6. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
7. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
8. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
9. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)

HDAC5 (50045)

1. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
2. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
3. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
4. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.z

HDAC6 (50006)

1. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function (2017)
2. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration (2017)
3. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies (2017)
4. Molecular Simulation and Activity Studies of Oxametacin as an HDAC Inhibitor (2017)
5. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
6. Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity (2017)
7. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
8. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy (2017)
9. Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy (2017)
10. HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice (2017)
11. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015) 
12. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
13. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
14. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors(2014) 
15. Thermodynamics of ligand binding to histone deacetylase like amidohydrolase from Bordetella/Alcaligenes (2014) 
16. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
17. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
18. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
19. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform (2013) 
20. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013) 
21. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors(2013)

HDAC7 (50007)

1. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017) 
2. In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases(2017)
3. Structural Characterization of the SMRT Corepressor Interacting with Histone Deacetylase (2017)
4. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
5. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
6. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
7. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
8. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)

HDAC8 (50008)

1. An azumamide C analogue without the zinc-binding functionality (2017)
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity (2017)
3. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
4. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
4. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
2. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
3. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
4. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
5. Thermodynamics of ligand binding to histone deacetylase like amidohydrolase from Bordetella/Alcaligenes (2014) 
6. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
7. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
8. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
9. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
10. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013)

HDAC9 (50009)

1. An azumamide C analogue without the zinc-binding functionality (2017)
2. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
3. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
4. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
5. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
6. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
7. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
8. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group (2013)

HDAC10 (50010)

1. An azumamide C analogue without the zinc-binding functionality (2017)
2. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases (2015) 
3. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
4. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014)

HDAC11 (50011)

1. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.
2. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging.
3. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.

HDAC Class 2a Fluorogenic Assay Kit (50041)

1. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
2. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.
3. Association of downregulated HDAC 2 with the impaired mitochondrial function and cytokine secretion in the monocytes/macrophages from gestational diabetes mellitus patients

HDAC Fluorogenic Assay Kit (50033) 1. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
2. Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition (2014) 3. Mitogen-Activated Protein Kinase Phosphatase 3 (MKP-3)-Deficient Mice Are Resistant to Diet-Induced Obesity (2014)
4. Investigating the Selectivity of Metalloenzyme Inhibitors in the Presence of Competing Metalloproteins
5. Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties
6. Synthesis of Novel N-(2-Hydroxyphenyl)arylsulfonamides as Selective HDAC Inhibitory and Cytotoxic Agents
7. The Actin‐Binding Protein Cofilin and Its Interaction With Cortactin Are Required for Podosome Patterning in Osteoclasts and Bone Resorption In Vivo and In Vitro 
8. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity
HDAC1 Fluorogenic Assay Kit (50061)

1. A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1

2. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

HDAC2 Fluorogenic Assay Kit (50062)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

HDAC3 Fluorogenic Assay Kit (50073)

1. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

2. HDAC3 inhibition ameliorates spinal cord injury by immunomodulation

HDAC4 Fluorogenic Assay Kit (50064)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

HDAC6 Fluorogenic Assay Kit (50076)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

HDAC8 Fluorogenic Assay Kit (50068)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

Sirtuin 1 (193-741), GST-tag (50012)

1. SIRT4 Is a Lysine Deacylase that Controls Leucine Metabolism and Insulin Secretion (2017)
2. Lysine Deacetylases Exhibit Distinct Changes in Activity Profiles Due to Fluorophore Conjugation of Substrates (2017)
3. Development of High-Throughput Assays to Study Methylases, Demethylases and Deacetylases (2011)

Sirtuin 2, His-tag (50013)

Investigating the Sensitivity of NAD+-Dependent Sirtuin Deacylation Activities to NADH

Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors.

Sirtuin 3, GST-tag (50014)

Investigating the Sensitivity of NAD+-Dependent Sirtuin Deacylation Activities to NADH

Sirtuin 6, GST-tag (50017)

Investigating the Sensitivity of NAD+-Dependent Sirtuin Deacylation Activities to NADH

Sirtuin 1 Fluorogenic Assay Kit(50081)

1. Periodontal disease level-butyric acid putatively contributes to the ageing blood: A proposed link between periodontal diseases and the ageing process
2. Sirtuin1 Regulates the Stem Cell Therapeutic Effects on Regenerative Capability for Treating Severe Heart Failure in a Juvenile Animal Model
3. Zinc supplementation induces regulatory T cells by inhibition of Sirt‐1 deacetylase in mixed lymphocyte cultures

Sirtuin 2 Fluorogenic Assay Kit (50087)

SIRT2 interacts with β-catenin to inhibit Wnt signaling output in response to radiation-induced stress.

SIRT3 (Sirtuin3) Fluorogenic Assay Kit (50088)

1. Regulation of SIRT3 signal related metabolic reprogramming in gastric cancer by Helicobacter pylori oncoprotein CagA (2017)
2. Inhibition of myocardial reperfusion injury by ischemic postconditioning requires sirtuin 3-mediated deacetylation of cyclophilin D (2015)

Tubastatin A Hydrochloride (27108)

Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice (2017)

JARID1A (50110)

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth(2013)

Tetrazolylhydrazides as Selective Fragment‐Like Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A

JMJD2B (50111)

Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox (2017)

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

JMJD2C (50105)

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

JMJD2D (50117)

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

JMJD2E (50118)

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

JMJD3 (50115)

1. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.

2. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

LSD1 Substrate (50101)

1. 4SC-202 as a Potential Treatment for the Pediatric Brain Tumor Medulloblastoma (2017)
2. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate(2014)

LSD1 (KDM1A), Variant 2 (50097)

1. A scintillation proximity assay for histone demethylases (2014) 
2. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate(2014) 
3. Structural basis for histone mimicry and hijacking of host proteins by influenza virus protein NS1 (2014)
4. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency (2013) 
5. Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity (2013) 
6. Septins promote dendrite and axon development by negatively regulating microtubule stability via HDAC6-mediated deacetylation (2013)

LSD1 Chemiluminescent Assay Kit (50109)

1. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation (2013) 
2. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy (2013)

LSD1 (KDM1A) Fluorescent Assay Kit (50106)

1. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors(2017)
2. Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures (2015)

LSD1 Variant 1, GST-tag (50204)

1. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors (2017)
2. A scintillation proximity assay for histone demethylases (2014) 
3. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate(2014)

LSD1 (KDM1A), Variant 2 (50097)

1. A scintillation proximity assay for histone demethylases (2014) 
2. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate(2014) 
3. Structural basis for histone mimicry and hijacking of host proteins by influenza virus protein NS1 (2014)
4. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency (2013) 
5. Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity (2013) 
6. Septins promote dendrite and axon development by negatively regulating microtubule stability via HDAC6-mediated deacetylation (2013)

LSD1 (KDM1A), Variant 2, GST-tag (50100)

1. A scintillation proximity assay for histone demethylases (2014) 
2. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate(2014)

UTX (KDM6A) (50116)

1. Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction (2017)
2. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity (2013)

HSP90α Assay Kit; (50293)

1. Rational Design of Selective Adenine-Based Scaffolds for Inactivation of Bacterial Histidine Kinases(2017)
2. The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells (2015) 
3. Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15 (2013)

HSP90β Assay Kit (50294)

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein (2014)

HSP90α Assay Kit (50298)

1. Rational Design of Selective Adenine-Based Scaffolds for Inactivation of Bacterial Histidine Kinases(2017)
2. Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15. (2017)

HSP90α (50290)

1. The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells (2015) 
2. Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15 (2013)

Anti-TIGIT Antibody, PE-Labeled (50 ug) (71228-1)

CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer (2017)

B7-1 (CD80), Fc fusion (Human) HiP™ (71125)

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint (20

CD73 Inhibitor Screening Assay Kit (72055)

Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes (2017)

IDO1, His-tag (Human) (71182)

Identification and preliminary structure–activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors

IDO1 Inhibitor Screening Assay Kit (72021)

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

NFAT Reporter (Luc) – Jurkat Recombinant Cell Line (60621)

Interleukin 2 Secretion by T Cells for Detection of Biologically Active Staphylococcal Enterotoxin Type E

PD-1 / NFAT Reporter - Jurkat Recombinant Cell Line (60535)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

(+)-JQ1 (27400)

1. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains (2017)
2. Analysis of Chromatin Opening in Heterochromatic Non-Small cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment (2017)
3. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity (2017)
4. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations (2017)
5. Erratum: BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin (2017)
6. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia (2017)
7. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma (2017)
8. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function (2015) 
9. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1 (2015) 
10. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen (2014) 
11. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (2014) 
12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma (2013)

(+)-JQ1 (27401)

1. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains (2017)
2. Analysis of Chromatin Opening in Heterochromatic Non-Small cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment (2017)
3. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity (2017)
4. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations (2017)
5. Erratum: BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin (2017)
6. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia (2017)
7. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma (2017)
8. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function (2015) 
9. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1 (2015) 
10. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen (2014) 
11. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (2014) 
12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma (2013)

(+)-JQ1 (27402)

1. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains (2017)
2. Analysis of Chromatin Opening in Heterochromatic Non-Small cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment (2017)
3. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity (2017)
4. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations (2017)
5. Erratum: BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin (2017)
6. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia (2017)
7. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma (2017)
8. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function (2015) 
9. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1 (2015) 
10. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen (2014) 
11. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (2014) 
12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma (2013)

Anti-PCSK9 (71207)

1. Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor(2017)
2. PCSK9 is a critical regulator of the innate immune response and septic shock outcome (2014)
3. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor (2017)

Caspase-3/7 Inhibitor I (27741-1)

Oleate protects beta-cells from the toxic effect of palmitate by activating pro-survival pathways of the ER stress response

SAHA (27006)

Santacruzamate A, a Potent and Selective Histone Deacetylase Inhibitor from the Panamanian Marine Cyanobacterium cf. Symploca sp.

itagliptin (27106)

Euglena gracilis deoxyribonucleic acid polymerases: subcellular locations and variations during the cell cycle.

Tyrphostin AG (27035)

Simultaneous Analysis of Oral Antidiabetic Drug by LC-MS/MS

Abl Kinase (40411)

LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.

AKT1 (40003)

Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding.

CERK Substrate (150 reactions) (40618)

Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.

CERK Substrate (300 reactions) (40619)

Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.

EGFR, GST-tag (40187)

1. Synthesis, characterization and biological evaluation of formononetin derivatives as novel EGFR inhibitors via inhibiting growth, migration and inducing apoptosis in breast cancer cell line (2017)

2. First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents (2017)

3. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors (2013)

4. Cytotoxic epipolythiodioxopiperazine alkaloids from filamentous fungi of the Bionectriaceae (2012)

EGFR Kinase Assay Kit (40321)

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

elF4E (40530)

MNK1-Induced eIF-4E Phosphorylation in Myeloma Cells: A Pathway Mediating IL-6-Induced Expansion and Expression of Genes Involved in Metabolic and Proteotoxic Responses

GSK3β (40007)

1. Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD (2015) 
2. Induction of Gsk3β-β-TrCP interaction is required for late phase stabilization of β-catenin in canonical Wnt signaling (2014) 
3. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β (2014)

IGF-1R (40240)

1. A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor (2014)

2. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR

HA-1077 (27030)

Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs

Human/Mouse ERK2 (K52R), Inactive, His-tag (40056)

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity

mTOR/Raptor/mLST8 Complex (40300)

The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.

NEK2 (40009)

Nek2 phosphorylates and stabilizes β-catenin at mitotic centrosomes downstream of Plk1.

PDK1 (40080)

PDK1 controls upstream PI3K expression and PIP3 generation.

PLK1 Polo Box Domain, GST-tag (50301)

1. Different Modes of Visual Integration in the Lateral Geniculate Nucleus Revealed by Single-Cell-Initiated Transsynaptic Tracing (2017)
2. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication (2017)

Pl3 Kinase (40625)

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα (2013)

Sphingosine Kinase 1 (40610)

A High-Throughput Genetic Complementation Assay in Yeast Cells Identified Selective Inhibitors of Sphingosine Kinase 1 Not Found Using a Cell-Free Enzyme Assay

Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation (2014)

Sphingosine Kinase 2 (long) (40612)

Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation.

Sphingosine Kinase 2 (40611)

1. Synthesis and biological evaluation of carbocyclic analogues of pachastrissamine (2015) 
2. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation (2014)

U0126 (27012)

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition (2017)

SYK, Full length, GST-tag (40485)

Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells(2017)

VPS34, FLAG-tag (40690)

Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson's disease (2017)

Yes1, GST-Tag (40488)

An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes (2017)

PKM1, His-tag (40502)

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival (2017)

DNMT1 Chemiluminescent Assay Kit (52050L)

ATM mediates pRB function to control DNMT1 protein stability and DNA methylation (2013)

The design and synthesis of small molecule drugs to inhibit the epigenetic alterations caused by DNA methltransferase 1

PRMT1 Chemiluminescent Assay Kit (52004L)
1. Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites (2015) 
2. Arginine Methyltransferase 1 in the Nucleus Accumbens Regulates Behavioral Effects of Cocaine(2015) 

PRMT1 Homogeneous Assay Kit (52054) Novel symmetrical ureas as modulators of protein arginine methyl transferases (2013)
DNMT1 (51101) 1. Controlling senescence by PML and PML nuclear bodies (2017) 
2. Electrical Probes of DNA-Binding Proteins. (2017)
3. Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential(2014) 
4. DNA 5-methylcytosine demethylation activities of the mammalian DNA methyltransferases (2013) 
5. DNMT1-interacting RNAs block gene-specific DNA methylation (2013) 
6. Electrochemical assay for the signal-on detection of human DNA methyltransferase activity (2013) 
7. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX (2013)
DNMT3A (51103) DNA 5-methylcytosine demethylation activities of the mammalian DNA methyltransferases (2013)

EZH2/EED/SUZ12/RbAp48/AEBP2, FLAG-tag, His-tag (51004)
1. Development of High-Throughput Assays to Study Methylases, Demethylases and Deacetylases.
2. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro 
3. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethlyation. (2010)
EZH2 (Y641C) (51029)

1. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

2. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

EZH2 (non-complexed), His-GST-tags (Y641C) (50279)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer (2017)

EZH2 (A738T) /EED/SUZ12/RbAp48/AEBP2, FLAG-Tag, His-Tag (51061)

LATS2 Positively Regulates Polycomb Repressive Complex 2

EZH2 (E740K)/EED/SUZH12/RbAp48/AEBP2, FLAG-tag, His-tag (51032)

GSK3-BETA-MEDIATED EZH2 PHOSPHORYLATION SUPPRESSES METHYLATION OF H3K27 AND EZH2’S ONCOGENIC FUNCTIONS

Histone H2a (52021)

1. Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus.

2. Challenges in profiling and lead optimization of drug discovery for methyltransferases

3. HMGA2-mediated epigenetic regulation of Gata6 controls epithelial canonical WNT signaling during lung development and homeostasis

Histone H2b (52022)

Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus (2013)

Histone H2b (52026)

Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus (2013)

Histone H3 (52023)

Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus (2013)

Histone H3 (52027)

Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus (2013)

Histone H3 peptide (1-21), Trimethyl K9, Biotin-labeled (50350)

4‐Biphenylalanine‐ and 3‐Phenyltyrosine‐Derived Hydroxamic Acids as Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A

Histone H3 (2-58)(52013)

1. Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus.

2. HMGA2-mediated epigenetic regulation of Gata6 controls epithelial canonical WNT signaling during lung development and homeostasis

3. Comparison of a High-Throughput Mass Spectrometry Method and Radioactive Filter Binding to Assay the Protein Methyltransferase PRMT5

Histone H3 (K9) Assay Kit (52072)

DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway (2015)

Histone H4 (52024)

1. Small Molecule Inhibitors of the Human Histone Lysine Methyltransferase NSD2 / WHSC1 / MMSET Identified from a Quantitative High-Throughput Screen with Nucleosome Substrate (2017)
2.Differential mode of antimicrobial actions of arginine-rich and lysine-rich histones against Gram-positive Staphylococcus aureus (2013) 
3. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury (2013)

NSD1 (51024)

A Sensitive Luminescent Assay for the Histone Methyltransferase NSD1 and Other SAM-Dependent Enzymes (2014)

NSD3 (1021-1322) (WHSC1L1) (51036)

WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer

PRMT1, GST-tag (Sf9-derived) (51041)

1. A Sensitive Luminescent Assay for the Histone Methyltransferase NSD1 and Other SAM-Dependent Enzymes (2014) 
2. Selective inhibitors of bacterial t-RNA-(N(1)G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain (2013)

PRMT4 (CARM1), FLAG-tag (HEK293-derived) (51047)

Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1 (2017)

PRMT5 (51045)

1. Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases (2017)
2. Unique Features of Human Protein Arginine Methyltransferase 9 (PRMT9) and Its Substrate RNA Splicing Factor SF3B2 (2015)

Set7/Set9, GST-tag (E. coli-derived (51010)

Selective inhibitors of bacterial t-RNA-(N(1)G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain (2013)

PDE Assay Kit (60300)

1. Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes (2015) 
2. Repurposing cAMP-Modulating Medications to Promote β-Cell Replication (2014) 
3. Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445) (2013)
4. Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes (2015)

PDE1A, GST-tag (60010)

1. PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries (2017)
2. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
3. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015) 
4. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
5. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE1B (60011)

Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry(2013)

The selectivity and potency of the new PDE5 inhibitor TPN729MA.

PDE1C (60013)

1. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
2. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013)

PDE2A, GST-tag (60020)

1. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors (2017)
2. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631 (2017)
3. Active Site Coupling in PDE:PKA Complexes Promotes Resetting of Mammalian cAMP Signaling(2014)

PDE3A (484-end), GST-tag (60030)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
3. Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry(2013) 
4. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE3A Assay Kit (60330)

1. Novel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study (2017)
2. Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutyl]-4-methylquinolin-2(1H)-one on rat adipocytes (2015)

PDE3A Assay Kit (60706)

Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4- methylpiperidin-1-yl)-4-oxobutoxy]-4- methylquinolin-2(1H)-one on rat adipocytes

PDE3B, GST-tag (60031)

1. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
2. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
3. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013) 
4. Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells(2013)

PDE4A Assay Kit (60340)

Bioguidage search of active compounds from Waltheria indica L. (Malvaceae) used for asthma and inflammation treatment in Burkina Faso (2014)

GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells

Caractérisation chimique et biologique de Waltheria indica L. (Malvaceae), herbacée utilisée en médecine traditionnelle au Burkina Faso pour la prise en charge de l'asthme

Bioguidage search of active compounds from Waltheria indica L. (Malvaceae) used for asthma and inflammation treatment in Burkina Faso.

PDE4A1A, GST-tag (60040)

1. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
2. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

3.Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes

4. The selectivity and potency of the new PDE5 inhibitor TPN729MA.

PDE4A4B, GST-tag (60039)

Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses

Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings

PDE4B1, GST-tag (60041)

Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide

Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings

PDE4B2 (60042)

1. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
2. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice (2013)

PDE4B2 Assay Kit (60343)

Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors (2015)

PDE4C1, GST-tag (60044)

Synthesis of 2,2,4-trimethyl-1,2-dihydroquinolinyl substituted 1,2,3-triazole derivatives: their evaluation as potential PDE 4B inhibitors possessing cytotoxic properties against cancer cells.

Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.

The selectivity and potency of the new PDE5 inhibitor TPN729MA.

Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses

PDE4D2 (60048)

1. Selagintamarlin A: A Selaginellin Analogue Possessing a 1H-2-Benzopyran Core from Selaginella tamariscina (2017) 
2. Ultrasound Assisted Faster and Milder Approach to 6H-pyrido [1, 2-a] quinazolin-6-imine Derivatives as Potential Inhibitors of PDE4 (2017)
3. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
4. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015) 
5. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice (2013) 
6. Synthesis of 2,2,4-trimethyl-1,2-dihydroquinolinyl substituted 1,2,3-triazole derivatives: their evaluation as potential PDE 4B inhibitors possessing cytotoxic properties against cancer cells (2014)

PDE4D2 Assay Kit (60345)

1. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors (2015) 
2. Active components of ginger potentiate β-agonist-induced relaxation of airway smooth muscle by modulating cytoskeletal regulatory proteins (2014) 
3. Novel imidazophenoxazine-4-sulfonamides: their synthesis and evaluation as potential inhibitors of PDE4 (2013) 
4. Quercetin acutely relaxes airway smooth muscle and potentiates β-agonist-induced relaxation via dual phosphodiesterase inhibition of PLCβ and PDE4 (2013)

PDE4D7, GST-tag (60047)

Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses

Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings

PDE5A Assay Kit (60350)

Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity (2014)

PDE5A1, GST-tag (60050)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)
3. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
4. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
5. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
6. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015) 
7. Active Site Coupling in PDE:PKA Complexes Promotes Resetting of Mammalian cAMP Signaling(2014) 
8. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
9. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013) 
10. Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry(2013) 
11. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE6C, GST-tag (60062)

1. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
2. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
3. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)

4. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance.

5. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings

PDE7A, GST-tag (60070)

1. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
2. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)
3. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
4. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
5. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
6. PDE7A1 hydrolyzes cCMP (2014) 
7. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE7B, GST-tag, His-tag (60071)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015)

PDE8A1, GST-tag (60080)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
3. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
4. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
5. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
6. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)
7. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015) 
8. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
9. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013) 
10. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE9A2, GST-tag (60090)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
3. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
4. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
5. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)
6. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A(2015) 
7. Active Site Coupling in PDE:PKA Complexes Promotes Resetting of Mammalian cAMP Signaling(2014) 
8. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
9. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013) 
10. Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry(2013) 
11. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

PDE10A (60400)

Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility (2014)

PDE10A1 (60099)

1. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
2. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
3. Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10 (2015)

PDE10A2, GST-tag (60100)

Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings

PDE11A4, GST-tag (60110)

1. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
2. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions (2017)
3. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders (2017)
4. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties (2017)
5. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays (2017)
6. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. (2017)
7. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014) 
8. A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013) 
9. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

Rat PDE2A (60022)

A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition (2013)

Rat PDE10A, GST-tag (60102)

Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia.

Activated DNA (5x) (80605)

ENPP1 processes protein ADP‐ribosylation in vitro

AZD2281 (Olaparib) (27003)

Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction

PARP1, GST-tag (80501)

1. Identification of PARP14 inhibitors using novel methods for detecting auto-ribosylation (2017)
2. Poly(ADP-ribose) polymerase 1 (PARP1) associates with E3 ubiquitin-protein ligase UHRF1 and modulates UHRF1 biological functions (2014) 
3. Fragment-based ligand design of novel potent inhibitors of tankyrases (2013)

PARP1 Chemiluminescent Assay Kit (80551)

1. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons (2017)
2. Dichamanetin inhibits cancer cell growth by affecting ROS-related signaling components through mitochondrial-mediated apoptosis (2013) 
3. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor (2013)

PARP1 Chemiluminescent Assay Kit (384-well) (80569)

1. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons (2017)
2. Dichamanetin inhibits cancer cell growth by affecting ROS-related signaling components through mitochondrial-mediated apoptosis (2013) 
3. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor (2013)

PARP1 Colorimetric Assay Kit (80580)

Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy (2017)

PARP2 (80502)

1. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency (2013) 
2. Fragment-based ligand design of novel potent inhibitors of tankyrases (2013)

PARP2 Chemiluminescent Assay Kit (80552)

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors (2013)

PARP9. GST-tag, His-tag (80509)

1. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

2. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation

PARP14 (80514)

1. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

2. Palladium-catalyzed N-arylation of 2-aminobenzothiazole-4-carboxylates/carboxamides: facile synthesis of PARP14 inhibitors

NAD+ Biotin-Labeled (80610)

1. Structure-function analyses of a pertussis-like toxin from pathogenic Escherichia coli reveal a distinct mechanism of inhibition of trimeric G-proteins (2017)
2. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution (2017)
2. Activity-based assay for human mono-ADP-ribosyltransferases ARTD7/PARP15 and ARTD10/PARP10 aimed at screening and profiling inhibitors (2013)

TNKS1 Histone Ribosylation Colorometric Assay Kit (80582)

Small Molecules Inspired by the Natural Product Withanolides as Potent Inhibitors of Wnt Signaling(2017)

TNKS2 Histone Ribosylation Colorometric Assay Kit (80583)

Small Molecules Inspired by the Natural Product Withanolides as Potent Inhibitors of Wnt Signaling(2017)

TNKS1 Histone Ribosylation Assay Kit (80579)

Scaffold hopping approach on the route to selective tankyrase inhibitors (2014)

TNKS2 Histone Ribosylation Assay Kit (80578)

Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells (2015)

DPP8, GST-tag (80080)

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus (2017)

DPP9, GST-tag (80090)

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus (2017)

DPP3 (80203)

Neuropeptide Kyotorphin Impacts on Lipopolysaccharide-Induced Glucocorticoid-Mediated Inflammatory Response. A Molecular Link to Nociception, Neuroprotection, and Anti-Inflammatory Action(2017)

DPP4 (80040)

1. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus (2017)
2.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus (2013)

DPP4 Assay Kit (80204)

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats (2015)

DPP8 Assay Kit (80208)

1. Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4 (2017)
2. Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice (2015)

DPP9 Assay Kit (80209)

Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4 (2017)

FAP Assay Kit (80210)

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor -4ZYDPLA1 (2015)

Fluorogenic DPP substrate1 (80305)

Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors (2017)

Fluorogenic DPP substrate2 (80332)

Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors (2017)

POP Assay Kit (80106)

New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro (2017)

Renin (80200)

Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay (2017)

PTP1B Colorimetric Assay Kit (30019)

Protein-Tyrosine Phosphatase-1B Mediates Sleep Fragmentation-Induced Insulin Resistance and Visceral Adipose Tissue Inflammation in Mice (2017)

PTPMT1 (30026)

The pseudophosphatase MK-STYX physically and genetically interacts with the mitochondrial phosphatase PTPMT1 (2014)

STYXL1 (30027)

The pseudophosphatase MK-STYX physically and genetically interacts with the mitochondrial phosphatase PTPMT1 (2014)

Native Nucleosome (52039)

1. Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis(2017)
2. One-pot refolding of core histones from bacterial inclusion bodies allows rapid reconstitution of histone octamer (2015) 
3. Role of a non-canonical surface of Rad6 in ubiquitin conjugating activity (2015)

ACC1, His-tag (50200)

A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates(2015)

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

ACC2, His-tag (50201)

A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates(2015)Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

AMPK (A1/B1/G1), His-tags (40025)

Fyn phosphorylates AMPK to inhibit AMPK activity and AMP-dependent activation of autophagy

ASH1L (31147)

The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis (2015)

ATP Citrate Lyase, GST-tag (50255)

The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis (2015)

Cathepsin F (80003)

Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage (2015)

CDK4 (40094)

Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity (2015)

DNA Polymerase γ (POLG) (21001)

Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening (2015) 

EGFR (TTM90M, L858R), GST-tag (40350)

EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer

GPD1, His-tag (71092)

Human Endomyocardial Biopsy Specimen‐Derived Stromal Cells Modulate Angiotensin II‐Induced Cardiac Remodeling

HIPK4, GST-tag (40111)

AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin

Human PD-L1, His-tag (71104)

Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells (2015)

JMJD3 (KDM6B), FLAG-tag (50115)

1. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013) 
2. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen (2013)

MNK1, GST-tag (40078)

Determinación del papel de la proteína quinasa MNK1b en cáncer de mama y desarrollo de aptámeros como posibles herramientas para su regulación

NSD1, GST-tag (51024)

A Sensitive Luminescent Assay for the Histone Methyltransferase NSD1 and Other SAM-Dependent Enzymes (2014)

P300 CoREST, His-tag (50274)

Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation (2015)

PHGDH, His-tag (71079)

α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH)

SIP Lyase, His-tag (50300)

A high-throughput scintillation proximity assay for sphingosine-1-phosphate lyase (2014)

Sortase A Pentamutant, S. aureus, His-tag (71046)

Application of Multivalent Interactions for Recognition Imaging and Delivery of Therapeutics

Turbonuclease (50310)

1. An electrochemical DNA biosensor for trace amounts of mercury ion quantification

2. Different Modes of Visual Integration in the Lateral Geniculate Nucleus Revealed by Single-Cell-Initiated Transsynaptic Tracing

USP8, FLAG-tag (80358)

The Endosome-associated Deubiquitinating Enzyme USP8 Regulates BACE1 Enzyme Ubiquitination and Degradation